Short answer: for most women 45 or older with typical symptoms, there is no universal required hormone panel before starting HRT. Guidelines put the weight on a structured history, symptom review, and risk assessment. Routine estradiol and FSH testing is not recommended in that group; FSH has a narrower role when menopause is unusually early.
If you're picturing an extensive hormone panel as the gateway to starting HRT, the actual guidelines tell a different story. For most women, a real evaluation and thoughtful conversation matters more than a blood draw. Here's what's genuinely recommended.
There's No Universal "Required Labs" Panel
For most people considering hormone therapy, there's no standard list of required baseline labs. The real assessment is clinical: symptoms, menstrual and reproductive history, medical and family history, current medications, contraindications, cardiovascular and clotting risk, cancer history, whether you still have a uterus, and your actual treatment goals.[1] For otherwise healthy women 45 or older with typical symptoms, perimenopause and menopause are usually identified clinically rather than through lab testing — new vasomotor symptoms plus menstrual cycle changes for perimenopause, or 12 months without a period (without hormonal contraception) for menopause.[1]
What Actually Happens Before Starting
Starting HRT involves real shared decision-making: weighing estrogen-only versus combined therapy, oral versus transdermal routes, formulation, dose, duration, and whether you have a uterus. That last point matters because women with an intact uterus generally need adequate progestogen protection alongside systemic estrogen.[1] The prescriber should also screen for things that could make systemic HRT inappropriate or require specialist input — unexplained vaginal bleeding, prior estrogen-sensitive cancer, prior coronary disease, stroke, heart attack, blood clots, liver disease, or a personal or family history of elevated clotting risk.[3]
A higher VTE (blood clot) risk doesn't automatically rule out treatment, but it does shape the plan — guidelines recommend considering transdermal over oral HRT for higher-risk patients, and considering a hematology assessment first for those with a strong family history of clotting or hereditary clotting disorders.[1]Similarly, a personal history of breast cancer or elevated breast cancer risk calls for a fuller discussion of all options and referral to a clinician with menopause-specific expertise — a more specialized evaluation, not a routine hormone panel, is what's actually indicated here.[1]
Why Routine Hormone Testing Usually Isn't Recommended
This is the part that surprises people. Routine estradiol testing isn't recommended to diagnose perimenopause or menopause in women 45 and older — hormone levels fluctuate too much during the transition for a single measurement to reliably confirm what's happening or determine the right dose.[1] Guidelines also recommend against using AMH, inhibin A or B, antral follicle count, or ovarian volume to identify perimenopause or menopause in this age group.[1]Routine FSH testing generally isn't necessary either for women 45+ with typical symptoms — and it's specifically advised against in women using combined hormonal contraception or high-dose progestogen, since those treatments make results hard to interpret.[1]
FSH testing does have a real, narrower role: it's worth considering to help confirm menopause in women 40–45 with symptoms and cycle changes, and in women under 40 when menopause or primary ovarian insufficiency (POI) is suspected.[1]For suspected POI before 40 specifically, diagnosis shouldn't rest on one value — guidelines call for symptoms plus elevated FSH confirmed on two samples taken four to six weeks apart.[1]
What Labs Might Get Ordered — and Why
A clinician may order non-hormone tests when your history suggests another condition worth ruling out — a pregnancy test if that's possible, thyroid testing when thyroid disease is a plausible alternative explanation, or evaluation for abnormal uterine bleeding. These are individualized clinical decisions based on your specific picture, not mandatory baseline requirements for everyone.[3] Part of a full evaluation is also clarifying whether your symptoms are systemic (hot flashes, night sweats) or primarily genitourinary (vaginal dryness, pain with sex) — since genitourinary-only symptoms may call for low-dose vaginal estrogen instead of systemic HRT.[3]Standard preventive care still matters too — cervical and breast screening, blood pressure checks, evaluating new symptoms — but that's routine care, not "HRT lab monitoring" specifically.[3]
What monitoring actually looks like once you start: response is generally tracked by symptom relief, side effects, adherence, any new health events, and blood pressure or other clinically relevant measures — not by chasing a "target" estradiol, FSH, or progesterone number.[3] The Menopause Society recommends periodic reevaluation of the benefits and risks of continuing therapy as your age, time since menopause, symptoms, and health change.[2] Guidelines call for a review around 3 months after starting to check effectiveness and tolerability, then at least annually unless something specific requires an earlier check-in.[1]
Follow-Up and When to Flag Something
At follow-up visits, a clinician may adjust dose, route, estrogen formulation, or the progestogen regimen based on symptom control and side effects. For women with a uterus on systemic estrogen, any new, unscheduled bleeding more than six months after starting therapy should get evaluated rather than dismissed as routine.[3]
On the testing-to-customize-dosing question specifically: routine salivary or urine hormone testing shouldn't be used to customize HRT dosing. The Menopause Society considers both unreliable, since absorption and metabolism vary person to person, and states that serum hormone testing itself is only rarely needed.[3] Occasional hormone testing can make sense in specific situations — symptoms persisting despite treatment, doubts about absorption or adherence, unusually early menopause, or suspicion of another endocrine condition — but these are individualized exceptions, not a basis for requiring broad hormone panels before anyone can start FDA-approved therapy.[1]
The Bottom Line
A legitimate HRT evaluation is a real structured symptom review and medical-risk assessment, followed by symptom- and safety-based follow-up — not a lab order. If a provider leans almost entirely on a single hormone number, or sells extensive testing as universally necessary before any HRT conversation can happen, that doesn't reflect what major guidelines actually recommend.
Worth comparing how different providers describe their intake and evaluation process before choosing one — a real history-and-symptom review is the standard to look for.
Sources
- Menopause: Identification and Management (NG23), Recommendations — National Institute for Health and Care Excellence nice.org.uk
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society — The Menopause Society / Menopause menopause.org
- Hormone Therapy for Menopause — American College of Obstetricians and Gynecologists acog.org
Frequently Asked Questions
Do I need blood work before starting HRT?
Not routinely, for most women. Diagnosis and treatment decisions are primarily based on your symptoms and medical history — routine hormone testing isn't recommended for women 45 and older with typical symptoms.[1]
When is FSH testing actually useful?
Mainly for women 40–45 with symptoms and cycle changes, or under 40 when early menopause or primary ovarian insufficiency is suspected — not as a routine test for everyone.[1]
How is HRT dosing monitored once I start?
By symptom relief, side effects, and clinical measures like blood pressure — not by targeting a specific hormone level. Salivary and urine hormone testing aren't considered reliable for customizing dose.[3]
Should I be suspicious of a provider that requires extensive lab testing before any HRT discussion?
It's worth asking why. Major guidelines emphasize a thorough symptom and history review, not broad hormone panels, as the standard for baseline evaluation.[1]